You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Screening for Novel CBS Inhibitors for Cancer Therapy

    SBC: CBS THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide (H2S) in colorectal cancer: selective upregulation of cystathionine-b-synthase (CBS) and the subsequent production of H2S in colonic cancer cells serves as a pro-survival factor by stimulating tumor cell bioenergetics, growth, proliferation, migratio ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. F10: a novel therapeutic to treat refractory or relapsed AML

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: NCI

    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Protein Bound RNA Sequencing

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: NHGRI

    DESCRIPTION (provided by applicant): Protein-RNA interactions make a profound contribution to the regulatory logic of post- transcriptional control of gene expression. Tools to decipher this intricate layer of molecular interactions on a global scale are coming to the forefront of molecular biology and genomics. The most wide spread methodology to examine interactions of RNA binding proteins (RBPs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease

    SBC: MIRNA THERAPEUTICS, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. There is a clear need for more effective therapies to treat deadly pancreatic cancer disease. MicroRNAs (miRNA or miR) are a large group of short, noncoding RNAs that control posttranscriptional gene expression in human cells, and there is increasing evidence for the exi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. EKO Approach To Find Small Molecules That Perturb Protein Protein Interaction

    SBC: Small Molecule PPI Mimics LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): One of the major new frontiers in the pharmaceutical industry is the design of small molecules to perturb protein-protein interactions PPIs. Many medicinally validated protein targets involve PPIs, but the methods available to discover small molecules that perturb these are, on aggregate, inadequate. Small Molecule PPI Mimics LLC owns intellectual property cove ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Geriatric Symptom Protocols for Improved Triage in Offices and Assisted Living

    SBC: KEONA HEALTH, INC.            Topic: NINR

    DESCRIPTION (provided by applicant): For medical practices, a major challenge is managing the hundreds of telephone calls received daily, many of which are about new or worsening medical symptoms. Particularly difficult are calls from persons with little or no medical training about frail older persons living at home or in assisted living (AL) communities. Incoming calls are typically answered by ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of fluorescence-based receptor binding assays for the detection

    SBC: SEATOX RESEARCH INC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Harmful algal blooms (HABs) are becoming frequent occurrences off the coasts of the United States, particularly in coastal waters of New England, the Gulf of Mexico, and the Pacific Ocean. Historically, HABs have beenassociated with fish kills and marine mammal mortalities; however, their effects on human health and economic loss due to HAB contamination of se ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. R3: A Smart Attachment for Improving Adherence and Usage of Metered Dose Inhalers

    SBC: Cognita Labs, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Respiratory illnesses continue to be on the rise1-4, in particular, COPD alone impacts nearly 210 million globally 6. Metered Dose Inhaler (MDI) is the most common mechanism to deliver medicine, and is used by the patients for both maintenance and rescue medications. It is well established that regular use of the medications minimizes long-term damage to the lu ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Ovarian cancer using novel nanoparticle formulations

    SBC: KIROMIC BIOPHARMA INC            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government